JP2024533313A5 - - Google Patents

Info

Publication number
JP2024533313A5
JP2024533313A5 JP2024515069A JP2024515069A JP2024533313A5 JP 2024533313 A5 JP2024533313 A5 JP 2024533313A5 JP 2024515069 A JP2024515069 A JP 2024515069A JP 2024515069 A JP2024515069 A JP 2024515069A JP 2024533313 A5 JP2024533313 A5 JP 2024533313A5
Authority
JP
Japan
Prior art keywords
sequence
grna
mutation
gene
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533313A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/076063 external-priority patent/WO2023039440A2/en
Publication of JP2024533313A publication Critical patent/JP2024533313A/ja
Publication of JP2024533313A5 publication Critical patent/JP2024533313A5/ja
Pending legal-status Critical Current

Links

JP2024515069A 2021-09-08 2022-09-07 Hbbを調節する組成物及び方法 Pending JP2024533313A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163241994P 2021-09-08 2021-09-08
US63/241,994 2021-09-08
US202163250143P 2021-09-29 2021-09-29
US63/250,143 2021-09-29
US202263303900P 2022-01-27 2022-01-27
US63/303,900 2022-01-27
PCT/US2022/076063 WO2023039440A2 (en) 2021-09-08 2022-09-07 Hbb-modulating compositions and methods

Publications (2)

Publication Number Publication Date
JP2024533313A JP2024533313A (ja) 2024-09-12
JP2024533313A5 true JP2024533313A5 (cg-RX-API-DMAC7.html) 2025-09-17

Family

ID=85506910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515069A Pending JP2024533313A (ja) 2021-09-08 2022-09-07 Hbbを調節する組成物及び方法

Country Status (7)

Country Link
US (1) US20240252682A1 (cg-RX-API-DMAC7.html)
EP (1) EP4399307A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024533313A (cg-RX-API-DMAC7.html)
AU (1) AU2022342169A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231679A1 (cg-RX-API-DMAC7.html)
TW (1) TW202323524A (cg-RX-API-DMAC7.html)
WO (1) WO2023039440A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
AU2019327449B2 (en) 2018-08-28 2026-04-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
BR112022017715A2 (pt) 2020-03-04 2022-11-16 Flagship Pioneering Innovations Vi Llc Métodos e composições para modular um genoma
IL296095A (en) 2020-03-04 2022-11-01 Flagship Pioneering Innovations Vi Llc Improved methods and compositions for genome modulation
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CA3231712A1 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Pah-modulating compositions and methods
IL312965A (en) * 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and their uses
CN118251485A (zh) 2022-08-12 2024-06-25 宝洁公司 固体可溶性组合物
US12655369B2 (en) 2022-08-12 2026-06-16 The Procter & Gamble Company Solid dissolvable compositions comprising capsules
WO2024036117A1 (en) 2022-08-12 2024-02-15 The Procter & Gamble Company Low-water compositions
EP4684023A2 (en) * 2023-03-21 2026-01-28 Tessera Therapeutics, Inc. Modified template guide rna molecules
WO2024206125A1 (en) * 2023-03-24 2024-10-03 The Broad Institute, Inc. Use of prime editing for treating sickle cell disease
AU2024342487A1 (en) * 2023-09-13 2026-04-30 Tessera Therapeutics, Inc. Lipid nanoparticles for delivery of therapeutic payloads to cells
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026060316A1 (en) * 2024-09-13 2026-03-19 Tessera Therapeutics, Inc. Lipid nanoparticles for delivery of therapeutic payloads to cells
WO2026064481A1 (en) * 2024-09-20 2026-03-26 Harpe Bioherbicide Solutions, Inc. Glucosyltransferase genes conferring herbicide tolerance
WO2026099887A1 (en) * 2024-11-05 2026-05-15 Crisprbits Private Limited "guide rna and method of detection of sickle cell disease"

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6974349B2 (ja) * 2016-04-18 2021-12-01 クリスパー セラピューティクス アクチェンゲゼルシャフト ヘモグロビン異常症の処置のための材料及び方法
SG10202109385QA (en) * 2016-07-05 2021-10-28 Univ Johns Hopkins Crispr/cas9-based compositions and methods for treating retinal degenerations
WO2020191241A1 (en) * 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
AU2020344547A1 (en) * 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel nucleobase editors and methods of using same
US12435330B2 (en) * 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA

Similar Documents

Publication Publication Date Title
JP2024533312A5 (cg-RX-API-DMAC7.html)
JP2024533315A5 (cg-RX-API-DMAC7.html)
US5714353A (en) Safe vectors for gene therapy
JP6799058B2 (ja) アレル選択的な遺伝子編集およびその使用
EP3356520B1 (en) Lentiviral protein delivery system for rna-guided genome editing
JP2023529315A (ja) 機能的aavカプシドのハイスループット工学操作
US12129478B1 (en) Engineered adenosine deaminases and base editors thereof
JP2024533313A (ja) Hbbを調節する組成物及び方法
BR112020008733A2 (pt) método de resgate de códons de parada através de reatribuição genética com ace-trna
WO2016149484A2 (en) Compositions and methods for specific reactivation of hiv latent reservoir
WO2024131940A1 (zh) 融合物及其用途
JP2020530463A (ja) ウイルスの細胞内送達のためのペプチドおよびナノ粒子
JP2024525602A (ja) 切断不活性Cas12F1、切断不活性Cas12F1ベースの融合タンパク質、これを含むCRISPR遺伝子調節システム、その製造方法及び用途
JP7736329B2 (ja) Dux4遺伝子を標的とした顔面肩甲上腕型筋ジストロフィーの治療方法
WO2024238321A1 (en) Compositions and methods for targeted epigenetic modification
CN118147120A (zh) 胞苷脱氨酶及碱基编辑器
KR102876548B1 (ko) Francisella novicida Cas9 모듈 기반의 역전사 효소를 사용한 유전체 치환 및 삽입 기술
AU2022343271A1 (en) Recruitment in trans of gene editing system components
WO2021230385A1 (en) Method for treating muscular dystrophy by targeting utrophin gene
WO2022003608A1 (en) Mirna-485 inhibitor for huntington's disease
IL323066A (en) PAH Modulating Systems and Methods
JP2026509461A (ja) Serpina調節性組成物及び方法
JPH11502706A (ja) シュードタイプレトロウイルス粒子
JP2024522216A (ja) インフラマソーム関連疾患または障害を治療するためのmirna-485阻害剤の使用
RU2801848C1 (ru) Генетическая конструкция, адаптированная для доставки гена SMN1 человека с помощью аденоассоциированного вируса серотипа 2 для обеспечения нейроспецифичной экспрессии